TARGET – Real-World-Evidence study on the long-term benefits of MCT ®
-associated pollen allergoid SCIT on AR and asthma
Abstract
Background: Allergen immunotherapy (AIT) may have a long-term disease
modifying effect. The aim of this study is to demonstrate the long-term
benefit of MCT®-associated allergoid pollen SCIT (MCT®-associated -AIT)
on allergic rhinitis (AR) and asthma in clinical practice. Methods: In
this retrospective Real-World-Evidence (RWE) study the impact of AIT on
the progression of AR and onset of need for asthma medication was
analyzed using a German longitudinal database. Anonymized prescription
data of AR patients and exactly matched control patients aged from 5-65
years were analyzed. Results: Significantly less patients treated with
MCT®-associated-AIT did receive prescriptions for symptomatic AR
medication in the follow up period vs. control group (OR: 0.27;
p < 0.001). Further, significantly less asthmatic patients
under MCT®-associated-AIT did receive prescriptions for asthma
medications (OR: 0.48; p = 0.004). In addition, the prescriptions of AR
and asthma medication for MCT®-associated-AIT patients were
significantly reduced in the follow-up vs. baseline and control group
(24.2% and 35.6%, respectively, p < 0.001).The probability
of asthma medication onset in non-asthmatic patients during follow-up
was significantly reduced for AIT patients compared to controls (OR:
0.77, p = 0.001). All endpoints were significant for
children/adolescents and adults in the individual analyses. Conclusions:
This study gives evidence for long-term benefits up to 9.5 years of
MCT®-associated-AIT on the need for AR and new-onset asthma medication
in AR patients and asthma medication in asthmatics in an RWE setting.